WiseGuyReports.Com Publish a New Market Research Report On –“ Type 1 Diabetes (T1D) 2018 Global Market Outlook,Research,Trends and Forecast to 2023”.
Description:-
Type 1 diabetes (T1D) is an autoimmune disease that occurs when a person’s pancreas stops producing insulin, the hormone that controls blood-sugar levels. T1D develops when the insulin-producing pancreatic beta cells are mistakenly destroyed by the body’s immune system. The cause of this attack is still being researched, however scientists believe the cause may have genetic and environmental components.
Scope of the Report:
This report focuses on the Type 1 Diabetes (T1D) in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Sedentary lifestyle, unhealthy diet, lack of exercise and increasing prevalence of diabetes are key driver for Type 1 Diabetes (T1D) market. Insulin therapy is very much essential in the patients who have type 1 diabetes. Rising launch of the novel insulin formulations along with several adjunct therapies will positively impact the insulin acceptance. On the other hand, this chronic disorder poses a significant economic impact owing to the increasing cost of insulin coupled with other conditions such as cardiac disorders, kidney disease among others. While insulin therapy keeps people with T1D alive and can help keep blood-glucose levels within recommended range, it is not a cure, nor does it prevent the possibility of T1D’s serious effects. Although T1D is a serious and challenging disease, long-term management options continue to evolve, allowing those with T1D to have full and active lives. Asia Pacific region recorded the highest growth rate over the forecast period owing to the increasingly sedentary lifestyles, obese population, and improper food habits. North America accounted for more than 50% of the total market share over the forecast period.
Get a Sample Report @ https://www.wiseguyreports.com/sample-request/3493147-global-type-1-diabetes-t1d-market-2018-by
For more information or any query mail at sales@wiseguyreports.com
The worldwide market for Type 1 Diabetes (T1D) is expected to grow at a CAGR of roughly 4.4% over the next five years, will reach 2540 million US$ in 2023, from 1960 million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
Novo Nordisk
Sanofi
Eli Lilly
Merck
Boehringer Ingelheim
Samsung Bioepis
Biocon
Astellas
Janssen
Bristol-Myers Squibb
Lexicon
Sanofi
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Rapid Acting Insulin Analogs
Long Acting Insulin Analogs
Premix Insulin Analogs
Market Segment by Applications, can be divided into
Children
Adults
There are 15 Chapters to deeply display the global Type 1 Diabetes (T1D) market.
Chapter 1, to describe Type 1 Diabetes (T1D) Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Type 1 Diabetes (T1D), with sales, revenue, and price of Type 1 Diabetes (T1D), in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Type 1 Diabetes (T1D), for each region, from 2013 to 2018;
Continued……
Enquiry About Report @ https://www.wiseguyreports.com/enquiry/3493147-global-type-1-diabetes-t1d-market-2018-by
Table Of Contents – Major Key Points
1 Market Overview
1.1 Type 1 Diabetes (T1D) Introduction
1.2 Market Analysis by Type
1.2.1 Rapid Acting Insulin Analogs
1.2.2 Long Acting Insulin Analogs
1.2.3 Premix Insulin Analogs
1.3 Market Analysis by Applications
1.3.1 Children
1.3.2 Adults
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
http://heraldkeeper.com/economy/type-1-diabetes-t1d-2018-global-market-outlookresearchtrends-forecast-2023-159231.html
2 Manufacturers Profiles
2.1 Novo Nordisk
2.1.1 Business Overview
2.1.2 Type 1 Diabetes (T1D) Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Novo Nordisk Type 1 Diabetes (T1D) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Sanofi
2.2.1 Business Overview
2.2.2 Type 1 Diabetes (T1D) Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Sanofi Type 1 Diabetes (T1D) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Eli Lilly
2.3.1 Business Overview
2.3.2 Type 1 Diabetes (T1D) Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Eli Lilly Type 1 Diabetes (T1D) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Merck
2.4.1 Business Overview
2.4.2 Type 1 Diabetes (T1D) Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Merck Type 1 Diabetes (T1D) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Boehringer Ingelheim
2.5.1 Business Overview
2.5.2 Type 1 Diabetes (T1D) Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Boehringer Ingelheim Type 1 Diabetes (T1D) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Samsung Bioepis
2.6.1 Business Overview
2.6.2 Type 1 Diabetes (T1D) Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Samsung Bioepis Type 1 Diabetes (T1D) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Biocon
2.7.1 Business Overview
2.7.2 Type 1 Diabetes (T1D) Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Biocon Type 1 Diabetes (T1D) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Continued……
Buy 1-user PDF @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=3493147
For more information or any query mail at sales@wiseguyreports.com
CONTACT US:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Description:-
Type 1 diabetes (T1D) is an autoimmune disease that occurs when a person’s pancreas stops producing insulin, the hormone that controls blood-sugar levels. T1D develops when the insulin-producing pancreatic beta cells are mistakenly destroyed by the body’s immune system. The cause of this attack is still being researched, however scientists believe the cause may have genetic and environmental components.
Scope of the Report:
This report focuses on the Type 1 Diabetes (T1D) in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Sedentary lifestyle, unhealthy diet, lack of exercise and increasing prevalence of diabetes are key driver for Type 1 Diabetes (T1D) market. Insulin therapy is very much essential in the patients who have type 1 diabetes. Rising launch of the novel insulin formulations along with several adjunct therapies will positively impact the insulin acceptance. On the other hand, this chronic disorder poses a significant economic impact owing to the increasing cost of insulin coupled with other conditions such as cardiac disorders, kidney disease among others. While insulin therapy keeps people with T1D alive and can help keep blood-glucose levels within recommended range, it is not a cure, nor does it prevent the possibility of T1D’s serious effects. Although T1D is a serious and challenging disease, long-term management options continue to evolve, allowing those with T1D to have full and active lives. Asia Pacific region recorded the highest growth rate over the forecast period owing to the increasingly sedentary lifestyles, obese population, and improper food habits. North America accounted for more than 50% of the total market share over the forecast period.
Get a Sample Report @ https://www.wiseguyreports.com/sample-request/3493147-global-type-1-diabetes-t1d-market-2018-by
For more information or any query mail at sales@wiseguyreports.com
The worldwide market for Type 1 Diabetes (T1D) is expected to grow at a CAGR of roughly 4.4% over the next five years, will reach 2540 million US$ in 2023, from 1960 million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
Novo Nordisk
Sanofi
Eli Lilly
Merck
Boehringer Ingelheim
Samsung Bioepis
Biocon
Astellas
Janssen
Bristol-Myers Squibb
Lexicon
Sanofi
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Rapid Acting Insulin Analogs
Long Acting Insulin Analogs
Premix Insulin Analogs
Market Segment by Applications, can be divided into
Children
Adults
There are 15 Chapters to deeply display the global Type 1 Diabetes (T1D) market.
Chapter 1, to describe Type 1 Diabetes (T1D) Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Type 1 Diabetes (T1D), with sales, revenue, and price of Type 1 Diabetes (T1D), in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Type 1 Diabetes (T1D), for each region, from 2013 to 2018;
Continued……
Enquiry About Report @ https://www.wiseguyreports.com/enquiry/3493147-global-type-1-diabetes-t1d-market-2018-by
Table Of Contents – Major Key Points
1 Market Overview
1.1 Type 1 Diabetes (T1D) Introduction
1.2 Market Analysis by Type
1.2.1 Rapid Acting Insulin Analogs
1.2.2 Long Acting Insulin Analogs
1.2.3 Premix Insulin Analogs
1.3 Market Analysis by Applications
1.3.1 Children
1.3.2 Adults
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
http://heraldkeeper.com/economy/type-1-diabetes-t1d-2018-global-market-outlookresearchtrends-forecast-2023-159231.html
2 Manufacturers Profiles
2.1 Novo Nordisk
2.1.1 Business Overview
2.1.2 Type 1 Diabetes (T1D) Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Novo Nordisk Type 1 Diabetes (T1D) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Sanofi
2.2.1 Business Overview
2.2.2 Type 1 Diabetes (T1D) Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Sanofi Type 1 Diabetes (T1D) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Eli Lilly
2.3.1 Business Overview
2.3.2 Type 1 Diabetes (T1D) Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Eli Lilly Type 1 Diabetes (T1D) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Merck
2.4.1 Business Overview
2.4.2 Type 1 Diabetes (T1D) Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Merck Type 1 Diabetes (T1D) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Boehringer Ingelheim
2.5.1 Business Overview
2.5.2 Type 1 Diabetes (T1D) Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Boehringer Ingelheim Type 1 Diabetes (T1D) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Samsung Bioepis
2.6.1 Business Overview
2.6.2 Type 1 Diabetes (T1D) Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Samsung Bioepis Type 1 Diabetes (T1D) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Biocon
2.7.1 Business Overview
2.7.2 Type 1 Diabetes (T1D) Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Biocon Type 1 Diabetes (T1D) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Continued……
Buy 1-user PDF @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=3493147
For more information or any query mail at sales@wiseguyreports.com
CONTACT US:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
No comments:
Post a Comment